Tourmaline Bio Inc reports results for the quarter ended in March - Earnings Summary

Tourmaline Bio

13/05/2024 22:52

* Tourmaline Bio Inc  TRML.OQ  reported a quarterly adjusted
loss
of 55 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of $-5.40.  The mean expectation of six analysts for the quarter
was for a loss of 67 cents per share. Wall Street expected
results to range from -96 cents to -53 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Tourmaline Bio Inc's reported EPS for the quarter was a
loss
of 55 cents​.
    * The company reported a quarterly loss of $13.31 million.
    * Tourmaline Bio Inc shares had fallen by 36.7% this
quarter and
lost 44.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Tourmaline Bio
Inc is $57.00 
This summary was machine generated from LSEG data May 13 at
09:52 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.67          -0.55          Beat
 Dec. 31 2023                     -0.81